Cargo Therapeutics Stock

cargo-tx.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $131.46MM

Cargo Therapeutics is a biotechnology company that specializes in developing precision therapeutics for cancer treatment. Their proprietary technology platform enables the targeted delivery of small molecules and biologics to cancer cells, while minimizing off-target effects on healthy cells. The company's lead product candidate, CT-100, is a novel therapeutic that selectively targets cancer cells expressing the protein EphA2, which is overexpressed in a variety of solid tumors. Cargo Therapeutics aims to improve patient outcomes and reduce the toxicity of cancer treatments with their precision therapeutics.

Register To Buy and Sell Shares

For more details on financing and valuation for Cargo Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Cargo Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cargo Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.
Updated on: Feb 25, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.